SARS-COV-2. Origen, vacunas, variantes y el futuro de la pandemia

Palabras clave: virus, SAR-COV-2, vacunas, variabilidad

Resumen

Desde fines de 2019 estamos viviendo un evento pandémico único en la historia de la humanidad. El antecedente más cercano, por su duración ysus consecuencias fue la pandemia de la gripe de 1918. A pesar de las múltiples consecuencias de este evento para salud pública, hoy nos encontramos mucho mejor preparados para combatir esta virosis y tratar a los pacientes con COVID-19. Conocimos rápidamente la identidad y las principales características del agente etiológico y apoco másde un año de declarada la emergencia sanitaria se han desarrollado vacunas que vienen mostrando ser efectivas y seguras. El objetivo de este trabajoes repasar las principales características del virus SARS-COV-2ylas diferencias y similitudes con otros coronavirus relacionados. Revisaremos los tipos yel desempeño de las vacunas actualmente en uso, y los desafíos que enfrentamos ante el surgimiento de ciertas variantes virales.

Descargas

La descarga de datos todavía no está disponible.

Citas

Amit, S., Regev-Yochay, G. A., Afek, Kreiss, Y. and Leshem, E. (2021). Early rate reductions of SARSCoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. DOI: 10.1016/S0140-
6736(21)00448-7.

Andersen, K.G., Rambaut, A., Lipkin, W.I., Holmes, E.C., and Garry, R.F. (2020). The proximal origin of SARS-CoV-2. Nat. Med. DOI: 10.1038/s41591-020-0820-9.

Andrade, V.M., Christensen-Quick, A., Agnes, J. , Tur, C., Reed, R. Kalia, I. Marrero, D. Elwood, K. Schultheis, M. Purwar, E. Reuschel, T. McMullan, P. Pezzoli, K. Kraynyak, A. Sylvester, M.P. Mammen, P. Tebas, J.J. Kim, D.B. Weiner, T.R.F. Smith, S.J. Ramos, L.M. Humeau, J.D. Boyer, and K.E. Broderick (2021). INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARSCoV- 2 Variants. bioRxiv.

Anthony, S.J., R. Ojeda-Flores, O. Rico-Chavez, I. Navarrete-Macias, C.M. Zambrana-Torrelio, M.K. Rostal, J.H. Epstein, T. Tipps, E. Liang, M. Sanchez-Leon, J. Sotomayor-Bonilla, A.A. Aguirre, R. Avila-Flores, R.A. Medellin, T. Goldstein, G. Suzan, P. Daszak, and W.I. Lipkin, 2013: Coronaviruses in bats from Mexico. J Gen Viro l94, 1028–1038.

Baden, L.R., H.M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S.A. Spector, N. Rouphael, C.B. Creech, J. McGettigan, S. Khetan, N. Segall, J. Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B.S. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, H. Zhou, S. Han, M. Ivarsson, J. Miller, and T. Zaks (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. DOI: 10.1056/nejmoa2035389.

Banos, A., and J. Lacasa (2007). Spatio-temporal exploration of SARS epidemic. CyberGeo DOI: 10.4000/cybergeo.12803.

Cui, J., F. Li, and Z.L. Shi (2019). Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181–192, DOI: 10.1038/s41579-018-0118-9.

Dagan, N., N. Barda, E. Kepten, O. Miron, S. Perchik, M.A. Katz, M.A. Hernán, M. Lipsitch, B. Reis, and R.D. Balicer (2021). BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N. Engl. J. Med. DOI: 10.1056/nejmoa2101765.

DIGESA, MSP, U. (2021). MSP, Estudio de efectividad de vacunación anti SARS-CoV-2 en Uruguay en 2021 [Online] Available at https://www.gub.uy/ministerio-salud-publica/comunicacion/noticias/segundo-estudio-efectividad-vacunacion-antisars-cov-2-uruguay-8-junio-2021.

Fields B. (2013). Virology Fields, 6th edn. Vol. 2 (Knipe D.M., & Howley P.M., Eds.). Lippincott, Williams & Wilkins.

Folegatti, P.M., K.J. Ewer, P.K. Aley, B. Angus, S. Becker, S. Belij-Rammerstorfer, D. Bellamy, S. Bibi, M. Bittaye, E.A. Clutterbuck, C. Dold, S.N. Faust, A. Finn, A.L. Flaxman, B. Hallis, P. Heath, D. Jenkin, R. Lazarus, R. Makinson, A.M. Minassian, K.M. Pollock, M. Ramasamy, H. Robinson, M. Snape, R. Tarrant, M. Voysey, C. Green, A.D. Douglas, A.V.S. Hill, T. Lambe, S.C. Gilbert, A.J. Pollard, J. Aboagye, K. Adams, A. Ali, E. Allen, J.L. Allison, R. Anslow, E.H. Arbe-Barnes, G. Babbage, K. Baillie, M. Baker, N. Baker, P. Baker, I. Baleanu, J. Ballaminut, E. Barnes, J. Barrett, L. Bates, A. Batten, K. Beadon, R. Beckley, E. Berrie, L. Berry, A. Beveridge, K.R. Bewley, E.M. Bijker, T. Bingham, L. Blackwell, C.L. Blundell, E. Bolam, E. Boland, N. Borthwick, T.
Bower, A. Boyd, T. Brenner, P.D. Bright, C. Brown-O’Sullivan, E. Brunt, J. Burbage, S. Burge, K.R. Buttigieg, N. Byard, I. Cabera Puig, A. Calvert, S. Camara, M. Cao, F. Cappuccini, M. Carr, M.W.
Carroll, V. Carter, K. Cathie, R.J. Challis, S. Charlton, I. Chelysheva, J.-S. Cho, P. Cicconi, L. Cifuentes, H. Clark, E. Clark, T. Cole, R. Colin-Jones, C.P. Conlon, A. Cook, N.S. Coombes, R. Cooper, C.A. Cosgrove, K. Coy, W.E.M. Crocker, C.J. Cunningham, B.E. Damratoski, L. Dando, M.S. Datoo, H. Davies, H. De Graaf, T. Demissie, C. Di Maso, I. Dietrich, T.
Dong, F.R. Donnellan, N. Douglas, C. Downing, J. Drake, R. Drake-Brockman, R.E. Drury, S.J. Dunachie, N.J. Edwards, F.D.L. Edwards, C.J. Edwards, S.C. Elias, M.J. Elmore, K.R.W. Emary,
M.R. English, S. Fagerbrink, S. Felle, S. Feng, S. Field, C. Fixmer, C. Fletcher, K.J. Ford, J. Fowler, P. Fox, E. Francis, J. Frater, J. Furze, M. Fuskova, E. Galiza, D. Gbesemete, C. Gilbride, K. Godwin, G. Gorini, L. Goulston, C. Grabau, L. Gracie, Z. Gray, L.B. Guthrie, M. Hackett, S. Halwe, E. Hamilton, J. Hamlyn, B. Hanumunthadu, I. Harding, S.A. Harris, A. Harris, D. Harrison, C. Harrison, T.C. Hart, L. Haskell, S. Hawkins, I. Head, J.A. Henry, J. Hill, S.H.C. Hodgson, M.M. Hou, E. Howe, N. Howell, C. Hutlin, S. Ikram, C. Isitt, P. Iveson, S. Jackson, F. Jackson, S.W. James, M. Jenkins, E. Jones, K. Jones, C.E. Jones, B. Jones, R. Kailath, K. Karampatsas, J. Keen, S. Kelly, D. Kelly, D. Kerr, S. Kerridge, L. Khan, U. Khan, A. Killen, J. Kinch, T.B. King, L. King, J. King, L. Kingham-Page, P. Klenerman, F. Knapper, J.C. Knight, D. Knott, S. Koleva, A. Kupke, C.W. Larkworthy, J.P.J. Larwood, A. Laskey, A.M. Lawrie, A. Lee, K.Y. Ngan Lee, E.A. Lees, H. Legge, A. Lelliott,
N.-M. Lemm, A.M. Lias, A. Linder, S. Lipworth, X. Liu, S. Liu, R. Lopez Ramon, M. Lwin, F. Mabesa, M. Madhavan, G. Mallett, K. Mansatta, I. Marcal,
S. Marinou, E. Marlow, J.L. Marshall, J. Martin, J. cEwan, L. McInroy, G. Meddaugh, A.J. Mentzer, N. Mirtorabi, M. Moore, E. Moran, E. Morey, V. Morgan, S.J. Morris, H. Morrison, G. Morshead, R. Morter, Y.F. Mujadidi, J. Muller, T. Munera-Huertas, C. Munro, A. Munro, S. Murphy, V.J. Munster, P. Mweu, A. Noé, F.L. Nugent, E. Nuthall, K. O’Brien, D. O’Connor, B. Oguti, J.L. Oliver, C. Oliveira, P.J. O’Reilly, M. Osborn, P. Osborne, C. Owen, D. Owens, N. Owino, M. Pacurar, K. Parker, H. Parracho, M.
Patrick-Smith, V. Payne, J. Pearce, Y. Peng, M.P. Peralta Alvarez, J. Perring, K. Pfafferott, D. Pipini, E. Plested, H. Pluess-Hall, K. Pollock, I. Poulton, L. Presland, S. Provstgaard-Morys, D. Pulido, K. Radia, F. Ramos Lopez, J. Rand, H. Ratcliffe, T. Rawlinson, S. Rhead, A. Riddell, A.J. Ritchie, H. Roberts, J. Robson, S. Roche, C. Rohde, C.S. Rollier, R. Romani,
I. Rudiansyah, S. Saich, S. Sajjad, S. Salvador, L. Sanchez Riera, H. Sanders, K. Sanders, S. Sapaun, C. Sayce, E. Schofield, G. Screaton, B. Selby, C. Semple, H.R. Sharpe, I. Shaik, A. Shea, H. Shelton, S. Silk, L. Silva-Reyes, D.T. Skelly, H. Smee, C.C. Smith, D.J. Smith, R. Song, A.J. Spencer, E. Stafford, A. Steele, E. Stefanova, L. Stockdale, A. Szigeti, A. Tahiri-Alaoui, M. Tait, H. Talbot, R. Tanner, I.J. Taylor, V. Taylor, R. Te Water Naude, N. Thakur, Y. Themistocleous, A. Themistocleous, M. Thomas, T.M. Thomas, A. Thompson, S. Thomson-Hill, J.
Tomlins, S. Tonks, J. Towner, N. Tran, J.A. Tree, A. Truby, K. Turkentine, C. Turner, N. Turner, S. Turner, T. Tuthill, M. Ulaszewska, R. Varughese, N. Van Doremalen, K. Veighey, M.K. Verheul, I. Vichos, E. Vitale, L. Walker, M.E.E. Watson, B. Welham, J. Wheat, C. White, R. White, A.T. Worth, D. Wright, S. Wright, X.L. Yao, and Y. Yau, (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396, 467–478, DOI: 10.1016/S0140-6736(20)31604-4.

Gorbalenya, A.E., L. Enjuanes, J. Ziebuhr, and E.J. Snijder (2006). Nidovirales: Evolving the largest RNA virus genome. Virus Res. 117, 17–37, DOI: 10.1016/j.virusres.2006.01.017.

Keech, C., G. Albert, I. Cho, A. Robertson, P. Reed, S. Neal, J.S. Plested, M. Zhu, S. Cloney-Clark, H. Zhou, G. Smith, N. Patel, M.B. Frieman, R.E. Haupt, J. Logue, M. McGrath, S. Weston, P.A. Piedra, C. Desai, K. Callahan, M. Lewis, P. Price-Abbott, N. Formica, V. Shinde, L. Fries, J.D. Lickliter, P. Griffin, B. Wilkinson, and G.M. Glenn (2020). Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N. Engl. J. Med. 383, DOI: 10.1056/nejmoa2026920.

Ksiazek, T.G., D. Erdman, C.S. Goldsmith, S.R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, J.A. Comer, W. Lim, P.E. Rollin, S.F. Dowell, A.E. Ling, C.D. Humphrey, W.J. Shieh, J. Guarner, C.D. addock, P. Rota, B. Fields, J. DeRisi, J.Y. Yang, N. Cox, J.M. Hughes, J.W. LeDuc, W.J. Bellini, and L.J. Anderson (2003). A novel coronavirus associated with severe acute respiratory syndrome. N. Engl J. Med 348, 1953–1966.

Lau, S.K.P., P.C.Y. Woo, K.S.M. Li, Y. Huang, H.-W. Tsoi, B.H.L. Wong, S.S.Y. Wong, S.-Y. Leung, K.-H. Chan, and K.-Y. Yuen (2005). Severe acute respiratory
syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. U.S.A. DOI: 10.1073/pnas.0506735102.

Li, W., Z. Shi, M. Yu, W. Ren, C. Smith, J.H. Epstein, H. Wang, G. Crameri, Z. Hu, H. Zhang, J. Zhang, J. McEachern, H. Field, P. Daszak, B.T. Eaton, S. Zhang, and L.F. Wang, (2005). Bats are natural reservoirs of SARS-like coronaviruses. Science (80-.).310, 676–679.

Logunov, D.Y., I. V. Dolzhikova, D. V. Shcheblyakov, A.I. Tukhvatulin, O. V. Zubkova, A.S. Dzharullaeva, A. V. Kovyrshina, N.L. Lubenets, D.M. Grousova, A.S. Erokhova, A.G. Botikov, F.M. Izhaeva, O. Popova, T.A. Ozharovskaya, I.B. Esmagambetov, I.A. Favorskaya, D.I. Zrelkin, D. V. Voronina, D.N. Shcherbinin, A.S. Semikhin, Y. V. Simakova, E.A.
Tokarskaya, D.A. Egorova, M.M. Shmarov, N.A. Nikitenko, V.A. Gushchin, E.A. Smolyarchuk, S.K. Zyryanov, S. V. Borisevich, B.S. Naroditsky, and A.L. Gintsburg (2021). Safety and efficacy of an
rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet DOI: 10.1016/S0140-6736(21)00234-8.

Maier, H.J., E. Bickerton, and P. Britton (2015). Coronaviruses: Methods and Protocols. Coronaviruses Methods Protoc. Memish, Z.A., N. Mishra, K.J. Olival, S.F. Fagbo, V. Kapoor, J.H. Epstein, R. Alhakeem, A. Durosinloun, M. Al Asmari, A. Islam, A. Kapoor, T. Briese, P. Daszak, A.A. Al Rabeeah, and W.I. Lipkin (2013). Middle East respiratory syndrome coronavirus in
bats, Saudi Arabia. Emerg Infect Dis19, 1819–1823.

Monto, A.S., P.M. DeJonge, A.P. Callear, L.A. Bazzi, S.B. Capriola, R.E. Malosh, E.T. Martin, and J.G. Petrie (2020). Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan. J. Infect. Dis. 222, DOI: 10.1093/infdis/jiaa161.

Nalbandian, A., K. Sehgal, A. Gupta, M. V. Madhavan, C. McGroder, J.S. Stevens, J.R. Cook, A.S. Nordvig, D. Shalev, T.S. Sehrawat, N. Ahluwalia, B. Bikdeli,
D. Dietz, C. Der-Nigoghossian, N. Liyanage-Don, G.F. Rosner, E.J. Bernstein, S. Mohan, A.A. Beckley, D.S. Seres, T.K. Choueiri, N. Uriel, J.C. Ausiello, D. Accili, D.E. Freedberg, M. Baldwin, A. Schwartz, D. Brodie, C.K. Garcia, M.S.V. Elkind, J.M. Connors, J.P. Bilezikian, D.W. Landry, and E.Y. Wan, (2021). Postacute COVID-19 syndrome. Nat. Med. 27, DOI: 10.1038/s41591-021-01283-z.

Naveca, F., C. da Costa, V. Nascimento, V. Souza, A. Corado, Á. Nascimento, FernandaCosta, D. Duarte, G. Silga, M. Mejía, K. Pessoa, L. Gonçalves, M.J. Brandão, M. Jesus, R. Pinto, M. Silva, T. Mattos, L. Abdalla, J.H. Santos, R. Costa-Filho, G.L. Walllau, M. Mendonça Siqueira, N. Delatorre, T. Gräf, G. Bello, and P.C. Resende (2021). SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P.1 in Amazonas, Brazil. Virological.Org.

Palacios, R., A.P. Batista, C.S.N. Albuquerque, E.G. Patiño, J. do P. Santos, M. Tilli Reis Pessoa Conde, R. de O. Piorelli, L.C. Pereira Júnior, S.M. Raboni, F. Ramos, G.A. Sierra Romero, F.E. Leal, L.F.A. Camargo, F.H. Aoki, E.B. Coelho, D.S. Oliveira, C.J.F. Fontes, G.C.S. Pileggi, A.L.L. de Oliveira, A.M. de Siqueira, D.B.L. de Oliveira, V.F. Botosso, G. Zeng, Q. Xin, M.M. Teixeira, M.L. Nogueira, and E.G. Kallas (2021). Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study. SSRN Electron. J. DOI: 10.2139/ssrn.3822780.

Polack, F.P., S.J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J.L. Perez, G. Pérez Marc, E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K. Koury, P. Li, W. V. alina, D. Cooper, R.W. Frenck, L.L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D.B. Tresnan, S. Mather, P.R. Dormitzer, U. Şahin, K.U. Jansen, and W.C. Gruber (2020). Safety and Efficacy of the
BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. DOI: 10.1056/nejmoa2034577.

Sadoff, J., M. Le Gars, G. Shukarev, D. Heerwegh, C. Truyers, A.M. de Groot, J. Stoop, S. Tete, W. Van Damme, I. Leroux-Roels, P.-J. Berghmans, M. Kimmel, P. Van Damme, J. de Hoon, W. Smith, K.E. Stephenson, S.C. De Rosa, K.W. Cohen, M.J. McElrath, E. Cormier, G. Scheper, D.H. Barouch, J. Hendriks, F. Struyf, M. Douoguih, J. Van Hoof, and
H. Schuitemaker (2021) Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. N. Engl. J. Med. DOI: 10.1056/nejmoa2034201.

Smith, I., and L.F. Wang (2013). Bats and their virome: An important source of emerging viruses capable of infecting humans. Curr. Opin. Virol. 3, 84–91, DOI: 10.1016/j.coviro.2012.11.006.

Song, Z., Y. Xu, L. Bao, L. Zhang, P. Yu, Y. Qu, H. Zhu, W. Zhao, Y. Han, and C. Qin (2019). From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses 11, 59, DOI: 10.3390/v11010059.

Wang, N., S.Y. Li, X. Lou Yang, H.M. Huang, Y.J. Zhang, H. Guo, C.M. Luo, M. Miller, G. Zhu, A.A. Chmura, E. Hagan, J.H. Zhou, Y.Z. Zhang, L.F. Wang, P. Daszak, and Z.L. Shi (2018). Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China. Virol. Sin. DOI: 10.1007/s12250-018-0012-7.

Xia, S., Y. Zhang, Y. Wang, H. Wang, Y. Yang, G.F. Gao, W. Tan, G. Wu, M. Xu, Z. Lou, W. Huang, W. Xu, B. Huang, H. Wang, W. Wang, W. Zhang, N. Li, Z. Xie, L. Ding, W. You, Y. Zhao, X. Yang, Y. iu, Q. Wang, L. Huang, Y. Yang, G. Xu, B. Luo, W. Wang, P. Liu, W. Guo, and X. Yang (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis. DOI: 10.1016/S1473-3099(20)30831-8.

Xie, X., Y. Liu, J. Liu, X. Zhang, J. Zou, C.R. Fontes- Garfias, H. Xia, K.A. Swanson, M. Cutler, D. Cooper, V.D. Menachery, S.C. Weaver, P.R. Dormitzer, and P.Y. Shi (2021). Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, DOI: 10.1038/s41591-021-01270-4.

Zhang, Y., G. Zeng, H. Pan, C. Li, Y. Hu, K. Chu, W. Han, Z. Chen, R. Tang, W. Yin, X. Chen, Y. Hu, X. Liu, C. Jiang, J. Li, M. Yang, Y. Song, X. Wang, Q. Gao, and F. Zhu
(2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, doubleblind, placebo-controlled, phase 1/2 clinical
trial. Lancet Infect. Dis. 21, DOI: 10.1016/S1473-3099(20)30843-4.
Publicado
2021-07-30
Cómo citar
Delfraro, A. (2021). SARS-COV-2. Origen, vacunas, variantes y el futuro de la pandemia. Educación En Ciencias Biológicas, 6(1), eRECB.6.1.4. https://doi.org/10.36861/RECB.6.1.4
Sección
Asuntos sociocientíficos